Cancer Research

The Cancer Research theme encompasses companies advancing the prevention, detection, and treatment of malignancies across the oncology pipeline. Core tracks include oncology drug discovery and clinical development, immuno-oncology and cell/gene therapies, precision medicine with biomarkers and companion diagnostics, genomics and liquid biopsy, plus research tools, CROs, and enabling platforms.The sector's total market cap is 1064.07 billion USD, with a 24h change of -0.13%. Among 6 constituents, 2 are up (33.33%) and 4 are down (66.67%). The top gainer is Novartis AG (NVS), with a 24h increase of +0.68%.Leaders hold up as breadth softens. Prioritize late-stage, well-funded names; trade key catalysts and manage risk around rates and regulatory timelines.